Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058)
安罗替尼联合第三代 EGFR 酪氨酸激酶抑制剂治疗寡转移进展的晚期 NSCLC 患者:一项回顾性研究 (ALTER-L058)
期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2025.1686364
Zhou, Fei; Zhuo, Minglei; Wang, Hongmin; Yang, Nong; Li, Jisheng; Jin, Shi; Han, Zhengxiang; Zeng, Guilin; Liu, Jun; Song, Yang; Wang, Kangwu; Huang, Dabing; Li, Ling; Chen, Jian; Bai, Jinghui; Ran, Fengming; Zhou, Caicun